Overview
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
Status:
Completed
Completed
Trial end date:
2007-03-01
2007-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.Phase:
Phase 3Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Metformin
Rosiglitazone
Sitagliptin Phosphate
Criteria
Inclusion Criteria:- Patient has Type 2 diabetes
- Currently taking metformin >1500 mg/day for at least 10 weeks
- Male or female
Exclusion Criteria:
- Patient has peripheral edema
- History of type 1 diabetes
- Patient required insulin within prior 8 weeks
- Have participated or are currently participating in another study with an
investigational compound or device within 12 weeks of starting this study
- Participating in a weight loss program